Emily R. Theisen
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
82
Citations
929
Est. group size
~4
Recurring co-author estimate
Active years
60
Publishing since 1967
Emily R. Theisen's research focuses on the molecular biology of Ewing sarcoma, a type of bone and soft-tissue cancer, with particular attention to a protein called LSD1 (lysine-specific demethylase 1) and its role beyond its typical enzymatic function. Her work explores how targeting LSD1 and related gene-regulation mechanisms, including the cancer-driving EWSR1::FLI1 fusion protein, might lead to new therapeutic strategies for sarcoma and other solid tumors.
Publication output was modest and variable from 2017-2022 but rose sharply in 2023 and has remained elevated through 2025, suggesting a recent increase in research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- <i>N</i> ′-(1-Phenylethylidene)benzohydrazide Cytotoxicity Is Lysine-Specific Demethylase 1 Independent and Linked to Iron–Sulfur Cluster Disruption in Ewing Sarcoma
ACS Pharmacology & Translational Science · 2025
- Abstract 1436: The nonenzymatic effects of LSD1
Cancer Research · 2025
- Abstract 4035: Elucidating the DNA binding dynamics of EWSR1::FLI1 using biochemical methods
Cancer Research · 2025
- N’-(1-phenylethylidene)-benzohydrazide cytotoxicity is LSD1 independent and linked to Fe-S cluster disruption in Ewing sarcoma
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Voriconazole (VCZ) therapeutic drug monitoring (TDM) for prophylaxis and treatment of invasive fungal diseases in hematology patients – daily clinical practice and evidence from clinical trials
Blood · 2025
- LSD1 Performs Demethylase-Independent and Context-Specific Roles in Ewing Sarcoma
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma
Frontiers in Oncology · 2023
- 13P Transcriptional profiling of FET-rearranged sarcomas in response to SP-2577
Annals of Oncology · 2022
- Abstract P087: Targeting LSD1 protein scaffolding function in FET-rearranged sarcomas with SP-2577
Molecular Cancer Therapeutics · 2021
- Reversible Inhibition of Lysine-Specific Demethylase 1 is a Novel Therapeutic Strategy for Solid Tumors
J. Willard Marriott Library · 2016
- bioRxiv (Cold Spring Harbor Laboratory)×10
- Cancer Research×5
- eLife×4
- Oncotarget×2
- Molecular Cancer Therapeutics×2
- Rachel D. Dreher
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Kirsten M. Johnson
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Pearlly S. Yan
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Alberto Ortega
Biochemistry, Genetics and Molecular Biology · Indiana University
- Humaira Gowher
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile